Inhibition of the RIPK4 enhances suppression of human melanoma growth through vitamin D signaling
Molecular and Cellular Endocrinology · 2025
DOI: 10.1016/j.mce.2025.112603 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2025. Verfasst von Bartlomiej Olajossy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics and Cancer Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa Street 7, 3…. Hauptthemen laut MEDLINE: Melanoma, Signal Transduction, Vitamin D, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIAMS NIH HHS, National Science Centre Poland.
Abstract (Originalsprache)
Downregulation of Receptor-Interacting Protein Kinase 4 (RIPK4) inhibits NF-κB and Wnt/β-catenin signaling in melanoma and xenograft growth in mice. The active form of vitamin D3 (1,25-D3), in addition to regulating calcium and phosphate metabolism in humans through the vitamin D receptor (VDR), can inhibit the NF-κB signaling pathway and can affect the proliferation and differentiation of normal and malignant cells, including melanoma. An hyperactive NF-κB pathway maintains the malignant behavior of melanoma, which can be influenced by both RIPK4 and activated VDR. As their interactions affecting the response to 1,25-D3 in melanoma have not been studied, we tested whether downregulation of RIPK4 affects the sensitivity of melanoma cells to 1,25-D3. Our results have shown that both siRIPK4 and CRISPR/Cas9-mediated RIPK4 knockout increase VDR expression in melanoma cells. Furthermore, a decrease in CYP24A1 expression and an increase in 1,25 D3-induced VDR levels were observed in cells with RIPK4 downregulation. Treatment with 1,25- D3 of RIPK4.KO cells, compared to their wild-type counterparts, significantly reduced proliferation in 2D and 3D culture (MTT or ATP assay) and decreased p-p65 and cyclin D1 levels in melanoma cells. These results indicate that RIPK4 knockout may enhance the therapeutic efficacy of 1,25-D3 against melanoma, which encourages further studies on targeting RIPK4 signaling for anti-melanoma effects in preclinical models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biophysics and Cancer Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa Street 7, 30-387, Krakow, Poland; Doctoral School of Exact and Natural Sciences,…
- Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA; Veteran Administration Medical Center, Birmingham, AL, USA.
- Department of Biophysics and Cancer Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa Street 7, 30-387, Krakow, Poland. Electronic address: a.wolnicka-glubisz@uj.edu.p…
Förderung
- BLRD VA
- NIAMS NIH HHS
- National Science Centre Poland
- DOD
- NIH
Zitieren
APA
Olajossy, B., Slominski, A. T., & Wolnicka-Glubisz, A. (2025). Inhibition of the RIPK4 enhances suppression of human melanoma growth through vitamin D signaling. Molecular and Cellular Endocrinology. https://doi.org/10.1016/j.mce.2025.112603
Vancouver
Olajossy B, Slominski AT, Wolnicka-Glubisz A. Inhibition of the RIPK4 enhances suppression of human melanoma growth through vitamin D signaling. Molecular and Cellular Endocrinology. 2025. doi:10.1016/j.mce.2025.112603
BibTeX
@article{Olajossy2025,
author = {Olajossy, Bartlomiej and Slominski, Andrzej T and Wolnicka-Glubisz, Agnieszka},
title = {Inhibition of the RIPK4 enhances suppression of human melanoma growth through vitamin D signaling},
journal = {Molecular and Cellular Endocrinology},
year = {2025},
doi = {10.1016/j.mce.2025.112603}
}
EUVIMED